GTHX vs. AKBA, ALDX, DSGN, QURE, ELYM, PYXS, GBIO, TSVT, PRLD, and OVID
Should you be buying G1 Therapeutics stock or one of its competitors? The main competitors of G1 Therapeutics include Akebia Therapeutics (AKBA), Aldeyra Therapeutics (ALDX), Design Therapeutics (DSGN), uniQure (QURE), Eliem Therapeutics (ELYM), Pyxis Oncology (PYXS), Generation Bio (GBIO), 2seventy bio (TSVT), Prelude Therapeutics (PRLD), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical preparations" industry.
G1 Therapeutics (NASDAQ:GTHX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking.
G1 Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.
G1 Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
G1 Therapeutics currently has a consensus target price of $8.67, suggesting a potential upside of 152.67%. Akebia Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 367.29%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than G1 Therapeutics.
24.2% of G1 Therapeutics shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 6.1% of G1 Therapeutics shares are held by company insiders. Comparatively, 4.1% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Akebia Therapeutics received 101 more outperform votes than G1 Therapeutics when rated by MarketBeat users. However, 66.03% of users gave G1 Therapeutics an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
Akebia Therapeutics has a net margin of -22.99% compared to G1 Therapeutics' net margin of -36.40%. Akebia Therapeutics' return on equity of 0.00% beat G1 Therapeutics' return on equity.
In the previous week, G1 Therapeutics had 18 more articles in the media than Akebia Therapeutics. MarketBeat recorded 21 mentions for G1 Therapeutics and 3 mentions for Akebia Therapeutics. G1 Therapeutics' average media sentiment score of 0.81 beat Akebia Therapeutics' score of 0.19 indicating that G1 Therapeutics is being referred to more favorably in the media.
Summary
Akebia Therapeutics beats G1 Therapeutics on 10 of the 17 factors compared between the two stocks.
Get G1 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
G1 Therapeutics Competitors List
Related Companies and Tools
